MassMutual Private Wealth & Trust FSB Raises Stock Holdings in Boston Scientific Co. (NYSE:BSX)

MassMutual Private Wealth & Trust FSB raised its stake in Boston Scientific Co. (NYSE:BSX) by 15.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 5,385 shares of the medical equipment provider’s stock after buying an additional 724 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Boston Scientific were worth $481,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. AE Wealth Management LLC grew its position in shares of Boston Scientific by 18.9% in the 2nd quarter. AE Wealth Management LLC now owns 16,261 shares of the medical equipment provider’s stock worth $1,252,000 after buying an additional 2,582 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in Boston Scientific by 71.6% in the second quarter. Thrivent Financial for Lutherans now owns 333,963 shares of the medical equipment provider’s stock worth $25,718,000 after purchasing an additional 139,392 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Boston Scientific by 8.2% during the second quarter. ProShare Advisors LLC now owns 216,039 shares of the medical equipment provider’s stock worth $16,637,000 after purchasing an additional 16,430 shares in the last quarter. Epoch Investment Partners Inc. lifted its holdings in shares of Boston Scientific by 10.8% during the 2nd quarter. Epoch Investment Partners Inc. now owns 8,616 shares of the medical equipment provider’s stock valued at $664,000 after purchasing an additional 840 shares during the last quarter. Finally, Gabelli Funds LLC boosted its position in shares of Boston Scientific by 93.8% in the 2nd quarter. Gabelli Funds LLC now owns 183,526 shares of the medical equipment provider’s stock worth $14,133,000 after purchasing an additional 88,826 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. The trade was a 93.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,989 shares of company stock valued at $2,702,261. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $100.90 on Wednesday. The firm has a market cap of $148.71 billion, a PE ratio of 83.39, a P/E/G ratio of 2.59 and a beta of 0.80. The business has a 50-day moving average price of $91.21 and a 200 day moving average price of $84.76. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a twelve month low of $59.85 and a twelve month high of $101.14.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the prior year, the company posted $0.50 EPS. The business’s quarterly revenue was up 19.3% on a year-over-year basis. Sell-side analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on BSX. Mizuho increased their price target on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Royal Bank of Canada increased their price objective on shares of Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Canaccord Genuity Group boosted their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Finally, Stifel Nicolaus upped their target price on Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.